Saturday, June 5, 2021 - Elmiron (pentosan polysulfate sodium) allegedly causes maculopathy, better known as night blindness, in women who have taken the drug regularly for many years. Hundreds of women that have experienced eyesight damage have filed lawsuits against Janssen Pharmaceuticals and Johnson & Johnson for failing to warn them of the hellacious side effect. Elmiron lawsuits have been consolidated into multidistrict litigation (MDL) in New Jersey to streamline repetitive procedures. MDL is preferred in trials that involve complex scientific issues in product liability cases so that a judge can determine which experts will be allowed to testify for each side. Plaintiffs in MDL have had similar experiences with the allegedly defective product or drug and have suffered similar physical injuries. Experts have posted the results of scientific studies in peer-reviewed journals and conclude that taking Elmiron may cause eyesight damage. Visit Elmiron eye lawsuits to learn more.
Scientists studying Elmiron have concluded that the drug causes damage to the macula. Elmiron also registers a particular signature that identifies it as the cause. Pigmentary maculopathy is when spots form on the macula that preventing light from entering. DrugWatch.com describes PM. "Pigmentary maculopathy is a unique type of maculopathy linked to the interstitial cystitis drug, Elmiron (pentosan polysulfate sodium). Some people who used the drug long-term for treating IC and bladder pain developed pigmented deposits that resemble little specks in the macula, according to a 2018 study by Drs." Researchers for the Emory Eye Center first discovered that patients taking Elmiron presented a consistent and unique pattern on the macula. The study consisted of women with an average age of 60 who had been taking Elmiron for nearly 20 years. Women in the study reported difficulty reading. "We describe a novel and possibly avoidable maculopathy associated with chronic exposure to PPS. Patients reported symptoms of difficulty reading and prolonged dark adaptation despite generally intact visual acuity and subtle funduscopic findings. Multimodal imaging and functional studies are suggestive of a primary RPE injury." Another study conducted in February 2021, and published in Clinical Ophthalmology concluded " A novel drug-induced maculopathy has been associated with PPS use with a distinct clinical constellation that can be accurately identified with multimodal imaging."
Elmiron plaintiffs are blaming Elmiron for causing them to develop pigmentary maculopathy (PM). PM is a permanent, irreversible, and progressive degeneration of the ability to see in less than optimal lighting conditions. Lawsuits against Janssen and Johnson & Johnson claim that the companies either knew or had an obligation to know that Elmiron caused vision damage. The companies enjoyed a monopoly as the only FDA-approved drug for treating interstitial cystitis (IC) since 1996 yet updated their product warning to include vision damage in 2020. Elmiron vision damage lawyers are interviewing potential plaintiffs that can demonstrate that they have been taking the drug and have a diagnosis of PM.